Delayed sentinel lymph node biopsy for ductal cancer in situ
Part of Cancer, Skin clinical trials.
This trial tests whether doing a sentinel lymph node biopsy later (after breast surgery) is a safe, accurate way to check if cancer has spread. It uses a special tracking shot that helps find the lymph nodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a pre-op diagnosis of ductal carcinoma in situ (DCIS), any grade and size
- You are planning surgery that may include a risk-reducing mastectomy and a plan for sentinel lymph node biopsy (SLND) at your center
- If your diagnosis was unclear or a higher-risk pre-cancer finding, your team is considering upfront SLND based on your test results
- You are not pregnant and not breastfeeding
- You do not have an allergy or intolerance to iron or the trial tracking medicine (including dextran or SPIO)
- You do not have a condition that causes too much iron in the body
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing a “sentinel lymph node biopsy” later (a delayed biopsy) can help assess whether cancer has spread to lymph nodes in people having a mastectomy for DCIS. It may help avoid unnecessary aggressive treatment if lymph nodes look normal.
This trial studies whether taking a sample from the sentinel lymph node (a first lymph node that can be involved) improves care compared with observation, after a breast cancer PET scan of the armpit area. It may help people with certain early breast cancers avoid unnecessary procedures if the lymph nodes look negative on scans.
This trial looks at whether some people with HER2-positive or HR-positive breast cancer can safely avoid a sentinel lymph node biopsy after chemotherapy. It tests a treatment approach based on how completely the breast tumor shrinks on MRI and whether lymph nodes look clear before treatment.
This study is checking a new way to find and remove lymph nodes that may contain cancer when there are only one or two affected nodes. The goal is to see if this method works well and to help guide further treatment.
This trial studies whether removing the abnormal breast cells with breast-conserving surgery only (without additional treatment) is enough for people with low-risk ductal carcinoma in situ (DCIS). It may help some patients avoid extra treatments if their risk is very low.
This trial studies whether you can safely avoid a lymph node biopsy in the armpit for early breast cancer when scans and exams look negative. It may reduce surgery-related side effects while still keeping cancer care on track.
Hear when a new DCIS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.